Distinguished in Pulmonary Tuberculosis

Leonid W. Lecca

Lima, LMA, PE 
Distinguished in Pulmonary Tuberculosis
Lima, LMA, PE 
OverviewLocationsClinical Research

Overview

Leonid Lecca practices in Lima, Peru. Mr. Lecca is rated as a Distinguished expert by MediFind in the treatment of Pulmonary Tuberculosis. His top areas of expertise are Pulmonary Tuberculosis, COVID-19, HIV/AIDS, and Severe Acute Respiratory Syndrome (SARS).

His clinical research consists of co-authoring 184 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 36 articles and participated in 2 clinical trials in the study of Pulmonary Tuberculosis.

Gender
Male

Locations

Lima, LMA, Peru
Other Locations
San Isidro, LOR, Peru

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial
Evaluating Newly Approved Drugs for Multidrug-resistant TB (endTB): A Clinical Trial
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: Bedaquiline, Delamanid, Clofazimine, Levofloxacin, Moxifloxacin, Linezolid, Pyrazinamide, MDR-TB regimen
Study Phase: Phase 3
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Enrollment Status: Completed
Publish Date: February 10, 2025
Intervention Type: Drug
Study Drugs: Bedaquiline, Delamanid, Clofazimine, Linezolid, MDR-TB regimen
Study Phase: Phase 3
Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB
Enrollment Status: Completed
Publish Date: May 24, 2023
Intervention Type: Drug
Study Phase: Phase 2
endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid
endTB (Expand New Drugs for TB) Observational Study: Treatment of MDR-TB With Regimens Containing Bedaquiline or Delamanid
Enrollment Status: Completed
Publish Date: June 13, 2022
Intervention Type: Other
View 3 Less Clinical Trials

184 Total Publications

The Hidden Epidemic: Post-Release Tuberculosis Risk in Formerly Incarcerated Populations.
The Hidden Epidemic: Post-Release Tuberculosis Risk in Formerly Incarcerated Populations.
Journal: Research square
Published: November 24, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Lecca's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile